A Phase 3 interventional study of Baricitinib and Placebo in Juvenile Idiopathic Arthritis, sponsored by Eli Lilly and Company. Completed at 86 sites in 20 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-10-07.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in Arthritis, Juvenile with a site in Japan — 3 open to participants now, 6 under way, 5 of them phase 3. Arthritis, Juvenile · Japan.
Among the 12 studies in Arthritis, Juvenile with a site in Japan, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2018, is one of 10 in phase 3, and was the 6th registered.
366 studies on the registry are indexed under Arthritis, Juvenile; 102 are open to participants now.
Browse Arthritis, Juvenile studies →3 of the 12 studies in Arthritis, Juvenile with a site in Japan are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Japan, United States, Argentina and 15 more countries
Ages 3+
AbbVie · Sites in Japan, United States, Argentina and 14 more countries
Ages 1–17
Eli Lilly and Company · Sites in Japan, Argentina, Australia and 17 more countries
Ages 1–18
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 69 Arthritis, Juvenile studies recruiting now, 13 (19%) set no upper age limit and 50 (72%) stop at 75 or younger; 65 take children under 18; 11 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 220 is above the median of 52 across 231 interventional studies indexed under Arthritis, Juvenile.
Median enrollment 58 across the 11 interventional studies, 113 across the 1 observational. Of the 6 that completed or were terminated, 6 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 8 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 4 studies filed under Arthritis, Juvenile — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in Arthritis, Juvenile with a site in Japan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The reason for this study is to see if the study drug baricitinib given orally is safe and effective in participants with JIA from 2 years to less than 18 years old.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Baricitinib was administered QD (once daily) as a 4-mg oral tablet for adolescent participants (12 to \<18 years of age) and children ≥9 years of age; and 2 mg for children \<9 years of age. Participants \<6 years of age received an oral suspension. Participants ≥6 to \<12 years old had the option of receiving an oral suspension. Participants \>12 years old were supplied tablets. The oral suspension dose was administered as 4-mg, 2-mg, 1-mg, and 0.5-mg as needed.
Drug: Baricitinib
Placebo matched to baricitinib was administered to participants during the DBW period.
Drug: Placebo
Administered orally.
Also known as: LY3009104
Administered orally.
Time to Disease Flare
A disease flare is defined as a worsening of 30% or more in at least three of the six core Paediatric American College of Rheumatology (PedACR) criteria for juvenile rheumatoid arthritis (JIA) and an improvement of 30% or more in no more than one of the criteria. The six PedACR criteria are: 1) the number of active joints, 2) the number of joints with limited range of motion, 3) physician's global assessment of disease activity, 4) parent's global assessment of the participant's overall well-being, 5) physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ) and 6) acute-phase reactant (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]), the ESR measure is only used as an acute phase reactant in the core criteria.
Time frame: Week 12 to Week 44
Percentage of Participants Achieving PedACR30 Responder Index
The PedACR30 response is defined as at least 30% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \>30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle visual analogue scale \[VAS\]), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.
Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44
Percentage of Participants Achieving PedACR50 Responder Index
The PedACR50 response is defined as at least 50% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.
Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44
Percentage of Participants Achieving PedACR70 Responder Index
The PedACR70 response is defined as at least 70% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.
Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44
Percentage of Participants Achieving PedACR90 Responder Index
The PedACR90 response is defined as at least 90% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.
Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44
Percentage of Participants Achieving PedACR100 Responder Index
The PedACR100 response is defined as at least 100% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.
Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44
Percentage of Participants With Inactive Disease
Inactive disease is defined as the presence of all of the following: 1. No joints with active arthritis based on Juvenile Arthritis Disease Activity Score (JADAS) - 27 score, 2. No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA as assessed by the investigator, 3. No active uveitis as assessed by the investigator, 4. Normal ESR or hsCRP (i.e., within normal limits in the local laboratory or, if elevated, not attributable to JIA), 5. Physician's Global Assessment of Disease Activity indicating no active disease (Score ranges are 0 to 100 and best possible score on scale is 0) and 6. Duration of morning stiffness ≤15 minutes.
Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44
Percentage of Participants With Minimal Disease Activity
Minimal disease activity is calculated based on the scores from the 1. Physician's Global Assessment of Disease Activity 2. Parent's Global Assessment of Well-Being and 3. the number of swollen joints. If the physician's global assessment of disease activity is ≤3.5 (score range: 0-100), the parent's global rating of patient's overall well-being is ≤2.5 (score range: 0-100), and the swollen joint count is ≤1 (score range: 0-73), then the participant reaches minimal disease activity. if not, minimal disease activity is not reached.
Time frame: Week 16, 20, 24, 28, 32, 36, 40 and 44
Percentage of Participants in Remission
Remission is defined as inactive disease for at least 24 consecutive weeks. Inactive disease is defined as the presence of all of the following: 1) No joints with active arthritis based on Juvenile Arthritis Disease Activity Score (JADAS)-27 score, 2) No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA as assessed by the investigator, 3) No active uveitis as assessed by the investigator, 4) Normal ESR or hsCRP (i.e., within normal limits in the local laboratory or, if elevated, not attributable to JIA), 5) Physician's Global Assessment of Disease Activity indicating no active disease (best possible score on scale \[0\]) and 6) Duration of morning stiffness ≤15 minutes.
Time frame: Week 28, 32, 36, 40 and 44
Change From Baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS-27) Score
The JADAS-27 score is based on 4 components: 1) Physician's global assessment of disease activity on a 0-100 mm VAS, 2) Parent's global assessment of overall well-being on a 0-100 mm VAS, 3) normalized ESR and 4) number of joints (maximum of 27) with active arthritis (cervical spine, elbows, wrists, metacarpophalangeal joints \[from first to third\], proximal interphalangeal joints, hips, knees, and ankles). The scores for the each of the first 3 components range from 0 -10; the score for the final component ranges from 0-27. The overall JADAS-27 score is sum of the 4 components and it ranges from 0-57. A higher score indicates more disease activity. Least square (LS) mean was calculated using Analysis of covariance (ANCOVA) model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.
Time frame: Baseline, Week 44
Change From Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item
CHAQ assesses the health status and physical function of children with juvenile arthritis over the past week. The CHAQ consists of a Disability Index and a Discomfort Index. The disability index consisted of 30 items grouped into the following 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 to 3 (0 = no difficulty; 1 = some difficulty; 2 = much difficulty and 3 = unable to do or not applicable). The scores of 8 domains were averaged to calculate the CHAQ-Disability Index total score. A higher score indicates worse physical function. The discomfort index consisted of Parent's Global Assessment of Well-Being and pain assessment due to illness. The intensity of pain is scored on a VAS scale ranging from 0-100 mm, with zero referring to "no pain" and 100 referring to "very severe pain". A higher score indicates a worse outcome.
Time frame: Baseline, Week 44
Change From Baseline in Psoriasis Area and Severity Index (PASI) Score
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk and legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.
Time frame: Baseline, Week 44
Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Index
The SPARCC enthesitis is an index used to measure the severity of enthesitis (sites at which tendons and ligaments attach to bones). The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.
Time frame: Baseline, Week 44
Change From Baseline in Juvenile Spondyloarthritis Disease Activity (JSpADA) Index
The JSpADA index is used to evaluate the disease activity of juvenile spondyloarthritis. The JSpADA index scores will be determined by following 8 components: active joint count, active enthesitis count, pain over the past week, CRP level related to juvenile spondyloarthritis activity, morning stiffness greater than 15 minutes, clinical sacroiliitis, uveitis and back mobility. All items are transformed to values of 0, 0.5, or 1, and the total score ranges from 0 to 8, where higher scores indicate more disease activity. LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.
Time frame: Baseline, Week 44
Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss)
Maximum Plasma Baricitinib Concentration at Steady-State
Time frame: For Safety/PK period: Day 1, Day 4, Day 14 (pre dose) and Day 14 (post dose). For OLLI period: Day 1, Day 14, Day 28, Day 56 and 84 (pre dose)
PK: Area Under the Baricitinib Concentration-Time Curve During a Dosing Interval at Steady-State (AUCτ,ss)
Area under the concentration-time curve of Baricitinib during a dosing interval at steady state.
Time frame: For Safety/PK period: Day 1, Day 4, Day 14 (pre dose) and Day 14 (post dose). For OLLI period: Day 1, Day 14, Day 28, Day 56 and 84 (pre dose)
Change From Baseline in Immunoglobulin Levels
Change from baseline in Serum Immunoglobulin A, Serum Immunoglobulin G and Serum Immunoglobulin M levels at week 12 are presented.
Time frame: Baseline, Week 12
Number of Participants With Change of Immunoglobulin G (IgG) Titers
Number of participants with change of IgG titers eligible for tetanus / diphtheria / acellular pertussis (tDaP) vaccine and pneumococcal conjugate are presented. Participants who were immunized with tDaP or pneumococcal conjugate vaccine had their IgG antibody titers to the antigens evaluated preimmunization and at 4 and 12 weeks postimmunization. A primary immune response was assessed in participants who had never received tDaP or pneumococcal conjugate vaccines previously and secondary/booster responses were assessed if the participants had previously received the vaccines. For pneumococcal conjugate vaccine, number of participants with \>= 2-fold increase from baseline in \>=6 pneumococcal serotypes at week 4 and 12 is presented. For tDaP vaccine, number of participants with \>= 4-fold increase from baseline in participants with baseline titer \>=0.1 IU/mL at week 4 and 12 is presented.
Time frame: Pre-Vaccination to 4 and 12 Weeks Post-Vaccination
Number of Participants With Product Acceptability and Palatability Assessment
The questionnaire for product acceptability and palatability assessed the participants ability to swallow the tablet, experience relating to the taste, smell and ease of administering and taking the suspension. The questionnaire contained following Questions: Question 1) How did you (your child) like the taste of the medicine? Question 2) How did you (your child) like the smell of the medicine? Question 3) How easy was it for you (your child) to take the medicine today? Question 4) How easy was it for you to use the oral syringe to give your child the dose today? and Question 5) How easy was it for you (your child) to swallow the medicine today? Responses: Liked Very Much, Liked, Neither Liked nor Disliked, Disliked, Disliked Very Much, Very Easy, Easy, Neither Easy nor Hard, Difficult (or Hard) and Very Difficult (or Hard). The number of participants with these responses are presented. Data is presented as "Question Number-Response-Time point".
Time frame: Baseline and week 12
Overall, 220 participants were enrolled: 29 started with the Pharmacokinetics (PK)/Safety period (2 weeks), and one participant was discontinued due to protocol deviation. 191 participants entered into the Open-label lead-in period (OLLI) period, and during week 2, 28 participants from the PK/Safety population entered into the OLLI period.
| Milestone | Baricitinib | Placebo |
|---|---|---|
| Started | 220 | 0 |
| Pk/safety period | 29 | 0 |
| Olli period | 219 | 0 |
| Received at least one dose of study drug | 220 | 0 |
| Completed | 163 | 0 |
| Not completed | 57 | 0 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Failure to meet randomization criteria | 39 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 0 |
| Withdrew: Due to epidemic or pandemic | 6 | 0 |
| Withdrew: Unexplainable flare disease | 1 | 0 |
| Withdrew: Protocol violation | 4 | 0 |
| Withdrew: Participant transitioned to jahx | 1 | 0 |
| Withdrew: Investigational product was not delivered to the site | 1 | 0 |
| Milestone | Baricitinib | Placebo |
|---|---|---|
| Started | 82 | 81 |
| Completed | 56 | 32 |
| Not completed | 26 | 49 |
| Withdrew: Adverse event | 2 | 2 |
| Withdrew: Failure to meet continuation criteria | 16 | 40 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Due to epidemic or pandemic | 5 | 6 |
| Withdrew: Study team decision | 1 | 0 |
A disease flare is defined as a worsening of 30% or more in at least three of the six core Paediatric American College of Rheumatology (PedACR) criteria for juvenile rheumatoid arthritis (JIA) and an improvement of 30% or more in no more than one of the criteria. The six PedACR criteria are: 1) the number of active joints, 2) the number of joints with limited range of motion, 3) physician's global assessment of disease activity, 4) parent's global assessment of the participant's overall well-being, 5) physical function as measured by the Childhood Health Assessment Questionnaire (CHAQ) and 6) acute-phase reactant (high-sensitivity C-reactive protein \[hsCRP\] and erythrocyte sedimentation rate \[ESR\]), the ESR measure is only used as an acute phase reactant in the core criteria.
| Weeks | Baricitinib | Placebo |
|---|---|---|
| Time to Disease Flare | NA (NA to NA) | 27.14 (15.29 to NA) |
The PedACR30 response is defined as at least 30% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \>30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle visual analogue scale \[VAS\]), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.
| Percentage of participants | Baricitinib | Placebo |
|---|---|---|
| At week 16 | 92.7 (87 to 98.3) | 81.5 (73 to 89.9) |
| At week 20 | 87.8 (80.7 to 94.9) | 64.2 (53.8 to 74.6) |
| At week 24 | 85.4 (77.7 to 93.0) | 55.6 (44.7 to 66.4) |
| At week 28 | 78 (69.1 to 87) | 51.9 (41 to 62.7) |
| At week 32 | 74.4 (64.9 to 83.8) | 49.4 (38.5 to 60.3) |
| At week 36 | 72.0 (62.2 to 81.7) | 44.4 (33.6 to 55.3) |
| At week 40 | 69.5 (59.5 to 79.5) | 38.3 (27.7 to 48.9) |
| At week 44 | 67.1 (56.9 to 77.2) | 38.3 (27.7 to 48.9) |
The PedACR50 response is defined as at least 50% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.
| Percentage of participants | Baricitinib | Placebo |
|---|---|---|
| At week 16 | 79.3 (70.5 to 88) | 75.3 (65.9 to 84.7) |
| At week 20 | 81.7 (73.3 to 90.1) | 58 (47.3 to 68.8) |
| At week 24 | 81.7 (73.3 to 90.1) | 49.4 (38.5 to 60.3) |
| At week 28 | 75.6 (66.3 to 84.9) | 50.6 (39.7 to 61.5) |
| At week 32 | 72 (62.2 to 81.7) | 46.9 (36 to 57.8) |
| At week 36 | 68.3 (58.2 to 78.4) | 43.2 (32.4 to 54) |
| At week 40 | 68.3 (58.2 to 78.4) | 38.3 (27.7 to 48.9) |
| At week 44 | 63.4 (53 to 73.8) | 37 (26.5 to 47.6) |
The PedACR70 response is defined as at least 70% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.
| Percentage of participants | Baricitinib | Placebo |
|---|---|---|
| At week 16 | 54.9 (44.1 to 65.6) | 54.3 (43.5 to 65.2) |
| At week 20 | 68.3 (58.2 to 78.4) | 45.7 (34.8 to 56.5) |
| At week 24 | 59.8 (49.1 to 70.4) | 37.0 (26.5 to 47.6) |
| At week 28 | 67.1 (56.9 to 77.2) | 39.5 (28.9 to 50.2) |
| At week 32 | 57.3 (46.6 to 68) | 35.8 (25.4 to 46.2) |
| At week 36 | 61 (50.4 to 71.5) | 35.8 (25.4 to 46.2) |
| At week 40 | 57.3 (46.6 to 68) | 30.9 (20.8 to 40.9) |
| At week 44 | 53.7 (42.9 to 64.5) | 35.8 (25.4 to 46.2) |
The PedACR90 response is defined as at least 90% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.
| Percentage of participants | Baricitinib | Placebo |
|---|---|---|
| At week 16 | 29.3 (19.4 to 39.1) | 23.5 (14.2 to 32.7) |
| At week 20 | 42.7 (32 to 53.4) | 24.7 (15.3 to 34.1) |
| At week 24 | 37.8 (27.3 to 48.3) | 21 (12.1 to 29.9) |
| At week 28 | 42.7 (32 to 53.4) | 25.9 (16.4 to 35.5) |
| At week 32 | 43.9 (33.2 to 54.6) | 27.2 (17.5 to 36.8) |
| At week 36 | 39 (28.5 to 49.6) | 27.2 (17.5 to 36.8) |
| At week 40 | 40.2 (29.6 to 50.9) | 23.5 (14.2 to 32.7) |
| At week 44 | 42.7 (32 to 53.4) | 23.5 (14.2 to 32.7) |
The PedACR100 response is defined as at least 100% improvement from baseline in 3 of any 6 variables in the core set, with no more than 1 of the remaining variables worsening by \> 30%. The 6 core response variables included in the PedACR criteria are: Number of active joints (defined as a joint that is swollen or in the absence of swelling has loss of passive motion accompanied by either pain on motion or joint tenderness) in 73 joints, Number of joints with limited range of motion in 69 joints, Physician's Global Assessment of Disease Activity (21-circle VAS), Parent's Global Assessment of Patient's Overall Well-being, Physical function as assessed by the CHAQ and Acute-phase reactant (hsCRP and ESR). When PedACR response is analyzed as secondary endpoint, ESR measure is only used as acute-phase reactant in the core criteria.
| Percentage of participants | Baricitinib | Placebo |
|---|---|---|
| At week 16 | 14.6 (7 to 22.3) | 17.3 (9 to 25.5) |
| At week 20 | 24.4 (15.1 to 33.7) | 19.8 (11.1 to 28.4) |
| At week 24 | 18.3 (9.9 to 26.7) | 16 (8.1 to 24) |
| At week 28 | 26.8 (17.2 to 36.4) | 19.8 (11.1 to 28.4) |
| At week 32 | 28 (18.3 to 37.8) | 21 (12.1 to 29.9) |
| At week 36 | 29.3 (19.4 to 39.1) | 21 (12.1 to 29.9) |
| At week 40 | 29.3 (19.4 to 39.1) | 17.3 (9 to 25.5) |
| At week 44 | 29.3 (19.4 to 39.1) | 16 (8.1 to 24) |
Inactive disease is defined as the presence of all of the following: 1. No joints with active arthritis based on Juvenile Arthritis Disease Activity Score (JADAS) - 27 score, 2. No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA as assessed by the investigator, 3. No active uveitis as assessed by the investigator, 4. Normal ESR or hsCRP (i.e., within normal limits in the local laboratory or, if elevated, not attributable to JIA), 5. Physician's Global Assessment of Disease Activity indicating no active disease (Score ranges are 0 to 100 and best possible score on scale is 0) and 6. Duration of morning stiffness ≤15 minutes.
| Percentage of participants | Baricitinib | Placebo |
|---|---|---|
| At week 16 | 12.2 (5.1 to 19.3) | 11.1 (4.3 to 18.0) |
| At week 20 | 13.4 (6.0 to 20.8) | 17.3 (9 to 25.5) |
| At week 24 | 17.1 (8.9 to 25.2) | 17.3 (9.0 to 25.5) |
| At week 28 | 20.7 (12.0 to 29.5) | 13.6 (6.1 to 21.0) |
| At week 32 | 22.0 (13.0 to 30.9) | 13.6 (6.1 to 21.0) |
| At week 36 | 23.2 (14.0 to 32.3) | 16.0 (8.1 to 24) |
| At week 40 | 20.7 (12.0 to 29.5) | 12.3 (5.2 to 19.5) |
| At week 44 | 23.2 (14.0 to 32.3) | 13.6 (6.1 to 21.0) |
Minimal disease activity is calculated based on the scores from the 1. Physician's Global Assessment of Disease Activity 2. Parent's Global Assessment of Well-Being and 3. the number of swollen joints. If the physician's global assessment of disease activity is ≤3.5 (score range: 0-100), the parent's global rating of patient's overall well-being is ≤2.5 (score range: 0-100), and the swollen joint count is ≤1 (score range: 0-73), then the participant reaches minimal disease activity. if not, minimal disease activity is not reached.
| Percentage of participants | Baricitinib | Placebo |
|---|---|---|
| At week 16 | 36.6 (26.2 to 47) | 40.7 (30 to 51.4) |
| At week 20 | 46.3 (35.5 to 57.1) | 33.3 (23.1 to 43.6) |
| At week 24 | 43.9 (33.2 to 54.6) | 34.6 (24.2 to 44.9) |
| At week 28 | 45.1 (34.4 to 55.9) | 33.3 (23.1 to 43.6) |
| At week 32 | 43.9 (33.2 to 54.6) | 32.1 (21.9 to 42.3) |
| At week 36 | 40.2 (29.6 to 50.9) | 33.3 (23.1 to 43.6) |
| At week 40 | 43.9 (33.2 to 54.6) | 32.1 (21.9 to 42.3) |
| At week 44 | 43.9 (33.2 to 54.6) | 27.2 (17.5 to 36.8) |
Remission is defined as inactive disease for at least 24 consecutive weeks. Inactive disease is defined as the presence of all of the following: 1) No joints with active arthritis based on Juvenile Arthritis Disease Activity Score (JADAS)-27 score, 2) No fever, rash, serositis, splenomegaly, hepatomegaly, or generalized lymphadenopathy attributable to JIA as assessed by the investigator, 3) No active uveitis as assessed by the investigator, 4) Normal ESR or hsCRP (i.e., within normal limits in the local laboratory or, if elevated, not attributable to JIA), 5) Physician's Global Assessment of Disease Activity indicating no active disease (best possible score on scale \[0\]) and 6) Duration of morning stiffness ≤15 minutes.
| Percentage of participants | Baricitinib | Placebo |
|---|---|---|
| At week 28 | 0 (0 to 0) | 0 (0 to 0) |
| At week 32 | 0 (0 to 0) | 1.2 (0 to 3.6) |
| At week 36 | 1.2 (0 to 3.6) | 4.9 (0.2 to 9.7) |
| At week 40 | 2.4 (0 to 5.8) | 3.7 (0 to 7.8) |
| At week 44 | 3.7 (0 to 7.7) | 3.7 (0 to 7.8) |
The JADAS-27 score is based on 4 components: 1) Physician's global assessment of disease activity on a 0-100 mm VAS, 2) Parent's global assessment of overall well-being on a 0-100 mm VAS, 3) normalized ESR and 4) number of joints (maximum of 27) with active arthritis (cervical spine, elbows, wrists, metacarpophalangeal joints \[from first to third\], proximal interphalangeal joints, hips, knees, and ankles). The scores for the each of the first 3 components range from 0 -10; the score for the final component ranges from 0-27. The overall JADAS-27 score is sum of the 4 components and it ranges from 0-57. A higher score indicates more disease activity. Least square (LS) mean was calculated using Analysis of covariance (ANCOVA) model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.
| score on a scale | Baricitinib | Placebo |
|---|---|---|
| Change From Baseline in Juvenile Arthritis Disease Activity Score-27 (JADAS-27) Score | -14.24 ± 1.006 | -9.91 ± 1.013 |
CHAQ assesses the health status and physical function of children with juvenile arthritis over the past week. The CHAQ consists of a Disability Index and a Discomfort Index. The disability index consisted of 30 items grouped into the following 8 domains: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities. Each item is scored from 0 to 3 (0 = no difficulty; 1 = some difficulty; 2 = much difficulty and 3 = unable to do or not applicable). The scores of 8 domains were averaged to calculate the CHAQ-Disability Index total score. A higher score indicates worse physical function. The discomfort index consisted of Parent's Global Assessment of Well-Being and pain assessment due to illness. The intensity of pain is scored on a VAS scale ranging from 0-100 mm, with zero referring to "no pain" and 100 referring to "very severe pain". A higher score indicates a worse outcome.
| score on a scale | Baricitinib | Placebo |
|---|---|---|
| Change From Baseline in Arthritis-Related Pain Severity as Measured by the Childhood Health Assessment Questionnaire (CHAQ) Pain Visual Analog Scale (VAS) Item | -29.65 ± 3.276 | -16.68 ± 3.202 |
PASI is a combined assessment of lesion severity and affected area into a single score: 0 (no disease) to 72 (maximal disease). Body is divided into 4 areas for scoring (head, arms, trunk and legs); each area is scored by itself and scores are combined for final PASI. For each area, percent of skin involved is estimated: 0 (0%) to 6 (90-100%), and severity is estimated by clinical signs, erythema, induration and desquamation; scale 0 (none) to 4 (maximum). Final PASI = sum of severity parameters for each area \* area score weight of section (head: 0.1, arms: 0.2 body: 0.3 legs: 0.4). LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.
| score on a scale | Baricitinib | Placebo |
|---|---|---|
| Change From Baseline in Psoriasis Area and Severity Index (PASI) Score | -1.14 ± 0.291 | -0.79 ± 0.354 |
The SPARCC enthesitis is an index used to measure the severity of enthesitis (sites at which tendons and ligaments attach to bones). The SPARCC assesses 16 sites for enthesitis using a score of "0" for no activity or "1" for activity. Sites assessed include Medial epicondyle (left/right \[L/R\]), Lateral epicondyle (L/R), Supraspinatus insertion into greater tuberosity of humerus (L/R), Greater trochanter (L/R), Quadriceps insertion into superior border of patella (L/R), Patellar ligament insertion into inferior pole of patella or tibial tubercle (L/R), Achilles tendon insertion into calcaneum (L/R), and Plantar fascia insertion into calcaneum (L/R). The SPARCC is the sum of all site scores (range 0 to 16). Higher scores indicate more severe enthesitis. LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.
| score on a scale | Baricitinib | Placebo |
|---|---|---|
| Change From Baseline in Spondyloarthritis Research Consortium of Canada (SPARCC) Index | -1.51 ± 0.276 | -1.95 ± 0.241 |
The JSpADA index is used to evaluate the disease activity of juvenile spondyloarthritis. The JSpADA index scores will be determined by following 8 components: active joint count, active enthesitis count, pain over the past week, CRP level related to juvenile spondyloarthritis activity, morning stiffness greater than 15 minutes, clinical sacroiliitis, uveitis and back mobility. All items are transformed to values of 0, 0.5, or 1, and the total score ranges from 0 to 8, where higher scores indicate more disease activity. LS mean was calculated using ANCOVA model which includes treatment, baseline, prior biologic JIA therapy, combined JIA category and predose exposure ESR category value as fixed factors.
| score on a scale | Baricitinib | Placebo |
|---|---|---|
| Change From Baseline in Juvenile Spondyloarthritis Disease Activity (JSpADA) Index | -2.56 ± 0.347 | -1.47 ± 0.296 |
Maximum Plasma Baricitinib Concentration at Steady-State
| Nanograms per milliliter (ng/mL) | 12 to <18 Years 4-mg QD | 9 to <12 Years 4-mg QD | 6 to <9 Years 2-mg QD | 2 to <6 Years 2-mg QD |
|---|---|---|---|---|
| Pharmacokinetics (PK): Maximum Plasma Baricitinib Concentration at Steady-State (Cmax, ss) | 57.7 ± 28 | 79 ± 33 | 56.8 ± 22 | 87.4 ± 38 |
Area under the concentration-time curve of Baricitinib during a dosing interval at steady state.
| hour*nanogram/millilitre (h*ng/mL) | 12 to <18 Years 4-mg QD | 9 to <12 Years 4-mg QD | 6 to <9 Years 2-mg QD | 2 to <6 Years 2-mg QD |
|---|---|---|---|---|
| PK: Area Under the Baricitinib Concentration-Time Curve During a Dosing Interval at Steady-State (AUCτ,ss) | 386 ± 45 | 500 ± 57 | 254 ± 27 | 410 ± 57 |
Change from baseline in Serum Immunoglobulin A, Serum Immunoglobulin G and Serum Immunoglobulin M levels at week 12 are presented.
| Milligrams per decilitre (mg/dL) | Baricitinib |
|---|---|
| Serum Immunoglobulin A | -15.98 ± 39.501 |
| Serum Immunoglobulin G | -81.46 ± 209.549 |
| Serum Immunoglobulin M | -9.86 ± 26.680 |
Number of participants with change of IgG titers eligible for tetanus / diphtheria / acellular pertussis (tDaP) vaccine and pneumococcal conjugate are presented. Participants who were immunized with tDaP or pneumococcal conjugate vaccine had their IgG antibody titers to the antigens evaluated preimmunization and at 4 and 12 weeks postimmunization. A primary immune response was assessed in participants who had never received tDaP or pneumococcal conjugate vaccines previously and secondary/booster responses were assessed if the participants had previously received the vaccines. For pneumococcal conjugate vaccine, number of participants with \>= 2-fold increase from baseline in \>=6 pneumococcal serotypes at week 4 and 12 is presented. For tDaP vaccine, number of participants with \>= 4-fold increase from baseline in participants with baseline titer \>=0.1 IU/mL at week 4 and 12 is presented.
| participants | Baricitinib |
|---|---|
| Tetanus toxoid containing vaccine at week 4 | 2 |
| Tetanus toxoid containing vaccine at week 12 | 2 |
| Diphtheria toxoid containing vaccine at week 4 | 2 |
| Diphtheria toxoid containing vaccine at week 12 | 1 |
| Pertussis toxin containing vaccine at week 4 | 2 |
| Pertussis toxin containing vaccine at week 12 | 2 |
| pneumococcal conjugate vaccine at week 4 | 3 |
| pneumococcal conjugate vaccine at week 12 | 2 |
The questionnaire for product acceptability and palatability assessed the participants ability to swallow the tablet, experience relating to the taste, smell and ease of administering and taking the suspension. The questionnaire contained following Questions: Question 1) How did you (your child) like the taste of the medicine? Question 2) How did you (your child) like the smell of the medicine? Question 3) How easy was it for you (your child) to take the medicine today? Question 4) How easy was it for you to use the oral syringe to give your child the dose today? and Question 5) How easy was it for you (your child) to swallow the medicine today? Responses: Liked Very Much, Liked, Neither Liked nor Disliked, Disliked, Disliked Very Much, Very Easy, Easy, Neither Easy nor Hard, Difficult (or Hard) and Very Difficult (or Hard). The number of participants with these responses are presented. Data is presented as "Question Number-Response-Time point".
| participants | Baricitinib |
|---|---|
| Question 1- Liked Very Much: Baseline | 2 |
| Question 1- Liked Very Much: Week 12 | 6 |
| Question 1- Liked: Baseline | 8 |
| Question 1- Liked: Week 12 | 2 |
| Question 1- Neither Liked nor Disliked: Baseline | 3 |
| Question 1- Neither Liked nor Disliked: Week 12 | 1 |
| Question 1- Disliked: Baseline | 0 |
| Question 1- Disliked: Week 12 | 1 |
| Question 1- Disliked Very Much: Baseline | 0 |
| Question 1- Disliked Very Much: Week 12 | 0 |
| Question 2- Liked Very Much: Baseline | 3 |
| Question 2- Liked Very Much: Week 12 | 2 |
| Question 2- Liked: Baseline | 7 |
| Question 2- Liked: Week 12 | 4 |
| Question 2- Neither Liked nor Disliked: Baseline | 3 |
| Question 2- Neither Liked nor Disliked: Week 12 | 2 |
| Question 2- Disliked: Baseline | 0 |
| Question 2- Disliked: Week 12 | 1 |
| Question 2- Disliked Very Much: Baseline | 0 |
| Question 2- Disliked Very Much: Week 12 | 1 |
| Question 3- Very Easy: Baseline | 8 |
| Question 3- Very Easy: Week 12 | 7 |
| Question 3- Easy: Baseline | 3 |
| Question 3- Easy: Week 12 | 2 |
| Question 3- Neither Easy nor Hard: Baseline | 1 |
| Question 3- Neither Easy nor Hard: Week 12 | 0 |
| Question 3- Difficult (or Hard): Baseline | 0 |
| Question 3- Difficult (or Hard): Week 12 | 1 |
| Question 3- Very Difficult (or Hard): Baseline | 1 |
| Question 3- Very Difficult (or Hard): Week 12 | 0 |
| Question 4- Very Easy: Baseline | 5 |
| Question 4- Very Easy: Week 12 | 8 |
| Question 4- Easy: Baseline | 6 |
| Question 4- Easy: Week 12 | 2 |
| Question 4- Neither Easy nor Hard: Baseline | 0 |
| Question 4- Neither Easy nor Hard: Week 12 | 0 |
| Question 4- Difficult (or Hard): Baseline | 0 |
| Question 4- Difficult (or Hard): Week 12 | 0 |
| Question 4- Very Difficult (or Hard): Baseline | 0 |
| Question 4- Very Difficult (or Hard): Week 12 | 0 |
| Question 5- Very Easy: Baseline | 146 |
| Question 5- Very Easy: Week 12 | 120 |
| Question 5- Easy: Baseline | 39 |
| Question 5- Easy: Week 12 | 34 |
| Question 5- Neither Easy nor Hard: Baseline | 14 |
| Question 5- Neither Easy nor Hard: Week 12 | 5 |
| Question 5- Difficult (or Hard): Baseline | 3 |
| Question 5- Difficult (or Hard): Week 12 | 0 |
| Question 5- Very Difficult (or Hard): Baseline | 1 |
| Question 5- Very Difficult (or Hard): Week 12 | 0 |
Collected over Baseline through Follow-up (Up To 341 Days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baricitinib PK and OLLI | 0/220 (0%) | 6/220 (2.7%) | 48/220 (21.8%) |
| Placebo DBW | 0/81 (0%) | 3/81 (3.7%) | 10/81 (12.3%) |
| Baricitinib DBW | 0/82 (0%) | 4/82 (4.9%) | 26/82 (31.7%) |
| Event | Baricitinib PK and OLLI | Placebo DBW | Baricitinib DBW |
|---|---|---|---|
| Juvenile idiopathic arthritisMusculoskeletal and connective tissue disorders | 1/220 | 1/81 | 0/82 |
| Suicide attemptPsychiatric disorders | 0/220 | 1/81 | 0/82 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 0/220 | 1/81 | 0/82 |
| Covid-19Infections and infestations | 0/220 | 0/81 | 1/82 |
| GastroenteritisInfections and infestations | 0/220 | 0/81 | 1/82 |
| HeadacheNervous system disorders | 0/220 | 0/81 | 1/82 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/220 | 0/81 | 1/82 |
| Decreased appetiteMetabolism and nutrition disorders | 1/220 | 0/81 | 0/82 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/220 | 0/81 | 0/82 |
| Joint destructionMusculoskeletal and connective tissue disorders | 1/220 | 0/81 | 0/82 |
| Event | Baricitinib PK and OLLI | Placebo DBW | Baricitinib DBW |
|---|---|---|---|
| Upper respiratory tract infectionInfections and infestations | 11/220 | 1/81 | 9/82 |
| HeadacheNervous system disorders | 14/220 | 3/81 | 8/82 |
| NasopharyngitisInfections and infestations | 19/220 | 3/81 | 6/82 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 11/220 | 3/81 | 6/82 |
| Oropharyngeal painRespiratory, thoracic and mediastinal disorders | 3/220 | 1/81 | 5/82 |
Baseline analysis Population includes all randomized participants.
| Age, Customized(Participants) | Baricitinib |
|---|---|
| Age — >=2 to <6 years | 6 |
| Age — >=6 to <9 years | 9 |
| Age — >=9 to <12 years | 30 |
| Age — >=12 to <18 years | 175 |
| Sex: Female, Male(Participants) | Baricitinib |
|---|---|
| Female | 152 |
| Male | 68 |
| Ethnicity (NIH/OMB)(Participants) | Baricitinib |
|---|---|
| Hispanic or Latino | 43 |
| Not Hispanic or Latino | 133 |
| Unknown or Not Reported | 44 |
| Race (NIH/OMB)(Participants) | Baricitinib |
|---|---|
| American Indian or Alaska Native | 7 |
| Asian | 48 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 152 |
| More than one race | 2 |
| Unknown or Not Reported | 6 |
| Region of Enrollment(Participants) | Baricitinib |
|---|---|
| Argentina | 20 |
| Czechia | 12 |
| Japan | 25 |
| United Kingdom | 11 |
| India | 6 |
| Spain | 14 |
| Russia | 8 |
| Austria | 2 |
| Turkey | 3 |
| Belgium | 7 |
| China | 18 |
| Brazil | 2 |
| Poland | 7 |
| Denmark | 1 |
| Italy | 11 |
| Mexico | 21 |
| Israel | 15 |
| France | 10 |
| Australia | 1 |
| Germany | 26 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Dec 2018 to primary completion in Jan 2022, 37 months.
Results were first posted in Oct 2022, 8 months after primary completion.
Of 36 phase 3 interventional studies under Arthritis, Juvenile, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 37 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Baricitinib